Treatment of severe sepsis: Where next? Current and future treatment approaches after the introduction of drotrecogin alfa

Vascular Health and Risk Management

Volumn 2, Issue 1, 2006, Pages 3-18

  Rice, Todd W ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drotrecogin alfa; High mobility group box protein; New therapies; Septic shock; Statins; Vasopressin

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ANTITHROMBIN III; BRAIN NATRIURETIC PEPTIDE; CATECHOLAMINE; CORTICOSTEROID; DROTRECOGIN; ETANERCEPT; FLUDROCORTISONE; HEPARIN; HIGH MOBILITY GROUP B1 PROTEIN; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; IMMUNOGLOBULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; KETOCONAZOLE; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PROCALCITONIN; PROSTAGLANDIN E1; PROTEIN C; PROTEINASE; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; UNINDEXED DRUG; VASOPRESSIN;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; BRAIN HEMORRHAGE; CARDIOGENIC SHOCK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG INFUSION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; ENZYME ACTIVITY; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; FIBRINOLYSIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOTENSION; INTESTINE ISCHEMIA; KIDNEY ISCHEMIA; LOW DRUG DOSE; LUNG EMBOLISM; MORTALITY; NEPHROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; RISK ASSESSMENT; SEPSIS; SEPTIC SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT FAILURE; TREATMENT PLANNING; VASOCONSTRICTION; VASODILATATION;

ADRENAL CORTEX HORMONES; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; ANTICOAGULANTS; ANTIDIURETIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY; HEMORRHAGE; HEPARIN; HMGB1 PROTEIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PATIENT SELECTION; PROTEIN C; RECOMBINANT PROTEINS; SEPSIS; SEVERITY OF ILLNESS INDEX; THROMBOPLASTIN; TREATMENT OUTCOME; VASOPRESSINS;

EID: 33646092057     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: 10.2147/vhrm.2006.2.1.3     Document Type: Review

References (142)

1. Abraham E, Arcaroli J, Carmody A, et al. 2000. HMG-1 as a mediator of acute lung inflammation. J Immun, 165:2950-4.
2. Abraham E, Reinhart K, Opal S, et al. The OPTIMIST Trial Study Group. 2003. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA, 290:238-47.
3. Abraham E, Laterre PF, Garg R, et al. 2005. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. New Engl J Med, 353:1332-41.
4. Aikawa M, Rabkin E, Sugiyama S, et al. 2001. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases, and tissue factor in vivo and in vitro. Circulation, 103:276-83.
5. Aikawa N, Fujishima S, Endo S, et al. 2005. Multicenter prospective study of procalcitonin as an indicator of sepsis. J Infect Chemother, 11: 152-9.
6. Aird WC. 2001. Vascular bed-specific hemostatsis: role of endothelium in sepsis pathogenesis. Crit Care Med, 29(Suppl 7):28-35.
7. Almog Y, Shefer A, Novack V, et al. 2004. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation, 110:880-5.
8. Andersson U, Wang H, Palmblad K, et al. 2000. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med, 192:565-70.
9. Angus DC, Linde-Zwirble WT, Clermont G, et al. 2003. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med, 31(1):1-11.
10. Angus DC, Linde-Zwirble WT, Lidicker J. 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med, 29:1303-10.
11. Annane D, Sebille V, Troche G, et al. 2000. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA, 283:1038-45.
12. Annane D, Sebille V, Charpentier C, et al. 2002. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA, 288:862-71.
13. Annane D, Briegel J, Keh D, et al. 2003. Clinical equipoise remains for issues of adrenocorticotropic hormone administration, cortisol testing, and therapeutic use of hydrocortisone. Crit Care Med, 31:2250-1.
14. Argenziano M, Choudhri AF, Oz MC, et al. 1997. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation, 96(9 Suppl): II-286-90.
15. Argenziano M, Chen JM, Choudhri AF, et al. 1998. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J Thor Cardiovasc Surg, 116:973-80.
16. Assicot M, Bendrel D, Carsin H, et al. 1993. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet, 341: 515-18.
17. Bernard GR, Vincent JL, Laterre PF, et al. 2001. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med, 344:699-709.
18. Bernard GR. 2003. Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis. Crit Care Med, 31:S85-93.
19. Bernard GR, Macias WL, Joyce DE, et al. 2003. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis. Critical Care, 7:155-63.
20. Bianchi ME, Beltrame M. 1988. Flexing DNA: HMG-box proteins and their partners. Am J Hum Genet, 63:1573-7.
21. Bianchi ME, Beltrame M, Paonessa G. 1989. Specific recognition of cruciform DNA by nuclear protein HMG1. Science, 243:1056-9.
22. Bollaert PE, Charpentier C, Levy B, et al. 1998. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med, 26:645-50.
23. Bonaldi T, Talamo F, Scaffidi P, et al. 2003. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. Embo J, 22:5551-60.
24. Bone RC, Balk RA, Cerra FB, et al. 1992. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest, 101:1644-55.
25. Bourque CW, Oliet SH. 1997. Osmoreceptors in the central nervous system. Ann Rev Phys, 59:601-19.
26. Briegel J, Forst H, Haller M, et al. 1999. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med, 27:723-32.
27. Brueckmann M, Huhle G, Lang S, et al. 2005. Prognostic value of plasma n-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation, 112:527-34.
28. Chen G, Li J, Ochani M, et al. 2004. Bacterial endotoxin stimulates macrophages to release HMGB1 partly through CD14- and TNF-dependent mechanisms. J Leuk Biol, 76:994-1001.
29. Clec'h C, Ferriere F, Karoubi P, et al. 2004. Diagnostic and prognostic value of procalcitonin in patients with septic shock. Crit Care Med, 32:1166-9.
30. Cooper DJ, Russell JA, Walley KR, et al for the VASST Investigators. 2003. Vasopressin (VP) and septic shock trial (VASST): innovative features and performance. Am J Resp Crit Care Med, 167:A838.
31. Cooper MS, Stewart PM. 2003. Corticosteroid insufficiency in acutely ill patients. N Engl J Med, 348:727-34.
32. Creasey AA, Chang ACK, Feigen L, et al. 1993. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest, 91:2850-60.
33. Creasey AA. 2000. New potential therapeutic modalities: Tissue factor pathway inhibitor. Sepsis, 3:173-82.
34. Cronin L, Cook DJ, Carlet J, et al. 1995. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med, 23:1430-9.
35. Davidson BL, Geerts WH, Lensing AWA. 2002. Low-dose heparin for severe sepsis. N Engl J Med, 347:1036-7.
36. Dellinger RP, Carlet JM, Masur H, et al. 2004. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med, 32:858-73.
37. [DHP] American Society of Health-System Pharmacists. 2005. Dear Healthcare Professional letter, Eli Lilly and Co, April 21, 2005 [online]. Accessed July 29, 2005. URL: www.ashp.org/news/ShowArticle.cfm?id=10698.
38. Dolovich LR, Ginsberg JS, Douketis JD, et al. 2000. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism. Arch Intern Med, 160:181-8.
39. Dunser MW, Mayr AJ, Ulmer H, et al. 2001. The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis. Anesth Analg, 93: 7-13.
40. Dunser MW, Mayr AJ, Ulmer H, et al. 2003. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation, 107:2313-19.
41. Dunzendorfer S, Rothbucher D, Schratzberger P, et al. 1997. Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin. Circ Res, 81: 963-9.
42. Eilertsen KE, Osterud B. 2004. Tissue factor: (patho)physiology and cellular biology. Blood Coagul Fibrinolysis, 15:521-38.
43. Einck L, Bustin M. 1985. The intracellular distribution and function of the high mobility group chromosomal proteins. Exp Cell Res, 156: 295-310.
44. Ely EW, Bernard GR, Vincent JL. 2002. Activated protein C for severe sepsis. N Engl J Med, 347:1035-6.
45. Esmon CT, Taylor FB Jr, Snow TR. 1991. Inflammation and coagulation: linked processes potentially regulated through a common pathway mediated by protein C. Thromb Haemost, 66:160-5.
46. Essig M, Nguyen G, Prie D, et al. 1998. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ Res, 83:683-90.
47. Falciola L, Spada F, Calogero S, et al. 1997. High mobility group 1 protein is not stably associated with the chromosomes of somatic cells. J Cell Biol, 137:19-26.
48. Finigan JH, Dudek SM, Singleton PA, et al. 2005. Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem, 280:17286-93.
49. Fiuza C, Bustin M, Talwar S, et al. 2003. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood, 101:2652-60.
50. Gauthier TW, Scalia R, Murohara T, et al. 1995. Nitric oxide protects against leukocyte-endothelium interactions in the early stages of hypercholesterolemia. Artherioscler Thromb Vasc Biol, 15:1652-9.
51. Gold J, Cullinane S, Chen J, et al. 2000a. Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure. Am J Card, 85:506-8.
52. Gold JA, Cullinane S, Chen J, et al. 2000b. Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension. Crit Care Med, 28:249-52.
53. Goodwin GH, Jones EW. 1977. The isolation and purification of the high mobility group (HMG) nonhistone chromosomal proteins. Methods Cell Biol, 16:257-67.
54. Graybiel A, Glendy RE. 1941. Circulatory effects following the intravenous administration of Pitressin in normal persons and in patients with hypertension and angina pectoris. Am Heart J, 21:481-9.
55. Harris HE, Andersson U. 2004. HMGB1 is highly conserved throughout evolution and consists of 215 amino acids. The nuclear protein HMG as proinflammatory mediator. Eur J Immunology, 34:1503-12.
56. Holmes CL, Patel BM, Russell JA, et al. 2001a. Physiology of vasopressin relevant to management of septic shock. Chest, 120:989-1002.
57. Holmes CL, Walley KR, Chittock DR, et al. 2001b. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Int Care Med, 27:1416-21.
58. Holmes CL, Walley KR. 2004. Vasopressin in the ICU. Curr Opin Crit Care, 10:442-8.
59. Hotchkiss RS, Karl IE. 2003. The pathophysiology and treatment of sepsis. N Engl J Med, 348:138-50.
60. Ibrahim EH, Sherman G, Ward S, et al. 2000. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest, 118:146-55.
61. Ignarro LJ, Buga GM, Wood KS, et al. 1987. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A, 84:9265-9.
62. Klinzing S, Simon M, Reinhart K, et al. 2003. High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med, 31:2646-50.
63. Kothe H, Dalhoff K, Rupp J, et al. 2000. Hydroxymethlglutaryl coenzyme a reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation, 101:1760-3.
64. Kreuzer J, Bader J, Janh L, et al. 1991. Chemotaxis of the monocytic cell line U937: dependence on cholesterol and early mevalonate pathway products. Atherosclerosis, 90:203-9.
65. Kubes P, Suzuki M, Granger DN. 1991. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A, 88: 4651-5.
66. Landry DW, Levin HR, Gallant EM, et al. 1997a. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med, 25: 1279-82.
67. Landry DW, Levin HR, Gallant EM, et al. 1997b. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation, 95: 1122-5.
68. Landry DW, Oliver JA. 2001. The pathogenesis of vasodilatory shock. N Engl J Med, 345:588-95.
69. Langer M, Riccardi F, Piovella F, et al. 2002. Use of anticoagulants in patients with sepsis. JAMA, 287:448-9.
70. Laszlo FA, Laszlo F Jr, DeWied D. 1991. Pharmacology and clinical perspectives of vasopressin antagonists. Pharm Rev, 43:73-108.
71. Laufs U, Fata VL, Liao JK. 1997. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem, 272:31725-9.
72. Laufs U, La Fata V, Plutzky J, et al. 1998. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation, 97:1129-35.
73. Lefering R, Neugebauer EA. 1995. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med, 23:1294-303.
74. Levi M, ten Cate H, van der Poll T, et al. 1993. Pathogenesis of disseminated intravascular coagulopathy in sepsis. JAMA, 270:975-9.
75. Levy MM, Fink MP, Marshall JC, et al. 2003.2001 SCCM/ESICM/ACCP/ATS/SIS International sepsis definitions conference. Crit Care Med, 31:1250-6.
76. Levy MM, Macias WL, Russell JA, et al. 2003. Failure to improve during first day of therapy is predictive of 28-day mortality in severe sepsis. Chest, 124(Suppl):120S.
77. Li J, Kokkola R, Tabibzadeh S, et al. 2003. Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol Med, 9:37-45.
78. Liappis AP, Kan VL, Rochester CG, et al. 2001. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis, 33:1352-7.
79. Macias WL, Yan SB, Williams MD, et al. 2005. New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated). Crit Care, 9(Suppl 4):S38-45.
80. Martin GS, Mannino DM, Eaton S, Moss M. 2003. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med, 348:1546-54.
81. Malay MB, Ashton RC Jr, Landry DW, et al. 1999. Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma, 47:699-703.
82. Malay MB, Ashton JL, Dahl K, et al. 2004. Heterogeneity of the vasoconstrictor effect of vasopressin in septic shock. Crit Care Med, 32:1327-31.
83. Matthay MA. 2001. Severe sepsis-a new treatment with both anticoagulant and antiinflammatory properties. N Engl J Med, 344:759-62.
84. Merx MW, Liehn EA, Janssens U, et al. 2004. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation, 109:2560-5.
85. Merx MW, Liehn EA, Graf J, et al. 2005. Statin treatment after onset of sepsis in a murine model improves survival. Circulation, 112: 117-24.
86. Meszaros K, Aberle S, Dedrick R, et al. 1994. Monocyte tissue factor induction by lipopolysaccharide (LPS): dependence on LPS-binding protein and CD14, and inhibition by a recombinant fragment of bactericidal/ permeability-increasing protein. Blood, 83:2516-25.
87. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. 1993. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood, 81:734-44.
88. Mosnier LO, Griffin JH. 2003. Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease activated receptor-1 and endothelial cell protein C receptor. Biochem J, 373:65-70.
89. Nick JA, Coldren CD, Geraci MW, et al. 2004. Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood, 104:3878-85.
90. Niwa S, Totsuka T, Hayashi S. 1996. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocytes cell line. Int J Immunopharmacol, 18:669-75.
91. Norsk P, Ellegaard P, Videbaek R, et al. 1993. Arterial pulse pressure and vasopressin release in humans during lower body negative pressure. Am J Phys, 264:R1024-30.
92. Osterud B, Rapaport SI. 1977. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci U S A, 74:5260-4.
93. Packard CJ. 1998. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation, 97:1440-5.
94. Pahan K, Sheikh FG, Namboodiri AM, et al. 1997. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest, 100:2671-9.
95. Patel BM, Chittock DR, Russell JA, et al. 2002. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesth, 96: 576-82.
96. Quail AW, Woods RL, Korner PI. 1987. Cardiac and arterial baroreceptor influences in release of vasopressin and renin during hemorrhage. Am J Phys, 252:H1120-6.
97. Quartin AA, Schein RM, Kett DH, et al. 1997. Magnitude and duration of the effect of sepsis on survival. JAMA, 277:1058-63.
98. Radomski MW, Rees DD, Dutra A, et al. 1992. S-Nitroso-glutathione inhibits platelet activation in vitro and in vivo. Br J Pharmocol, 107:745-9.
99. Rangel-Frausto MS, Pittet D, Costigan M, et al. 1995. The natural history of the systemic inflammatory response syndrome (SIRS). JAMA, 273:117-23.
100. Rendon-Mitchell B, Ochani M, Li J, et al. 2003. IFN-g induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J Immun, 170:3890-7.
101. Reid IA, Schwartz J. 1984. Role of vasopressin in the control of blood pressure. In: Martini L, Ganong WF (eds). Frontiers in Neuroendocrinology. New York: Raven Pr. p: 177-97.
102. Riedemann NC, Guo RF, Ward PA. 2003. Novel strategies for the treatment of sepsis. Nat Med, 9:517-24.
103. Rikitake Y, Kawashima S, Takeshita S, et al. 2001. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis, 154:87-96.
104. Rivers E, Nguyen B, Havstad S, et al. 2001. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med, 345:1368-77.
105. Sakai M, Kobori S, Matsumura T, et al. 1997. HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein. Athersclerosis, 133:51-9.
106. Scaffidi P, Misteli T, Bianchi ME. 2002. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature, 418:191-5.
107. Schmidt G, Bates B, McCollam JS, et al. 2003. Clinical use of drotrecogin alfa (activated): patients treated in mercury differ from those in prowess. Crit Care Med, 12(Suppl):A116.
108. Schrier RW, Berl T, Anderson RJ. 1979. Osmotic and nonosmotic control of vasopressin release. Am J Phys, 236:F321-32.
109. Schwartz J, Keil LC, Maselli J, et al. 1983. Role of vasopressin in blood pressure regulation during adrenal insufficiency. Endo, 112:234-8.
110. Sharshar T, Blanchard A, Paillard M, et al. 2003. Circulating vasopressin levels in septic shock. Crit Care Med, 31:1752-8.
111. Siegel JP. 2002. Assessing the use of activated protein C in the treatment of severe sepsis. N Engl J Med, 347:1030-4.
112. Sunden-Cullberg J, Norrby-Teglund A, Rouhiainen A, et al. 2005. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med, 33:564-73.
113. Swaab DF, Nijveldt F, Pool CW. 1975. Distribution of oxytocin and vasopressin in the rat supraoptic and paraventricular nucleus. J Endo, 67:461-2.
114. Takemoto M, Liao JK. 2001. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reducatase inhibitors. Arterioscler Thromb Vasc Biol, 21:1712-9.
115. Taylor FB Jr, Chang A, Ruf W, et al. 1991. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock, 33:127-34.
116. Thijs LG, deBoer JP, de Groot MCM, et al. 1993. Coagulation disorders in septic shock. Int Care Med, 19(Suppl 1):S8-15.
117. Treutiger CJ, Mullins GE, Johansson ASM, et al. 2003. High mobility group 1 B-box mediates activation of human endothelium. J Int Med, 254:375-85.
118. Tsuneyoshi I, Yamada H, Kakihana Y, et al. 2001. Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med, 29:487-93.
119. Tyrell DJ, Horne AP, Holme KR, et al. 1999. Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharm, 46:151-208.
120. Ugarte H, Silva E, Mercan D, et al. 1999. Procalcitonin used as a marker of infection in the intensive care unit. Crit Care Med, 27:498-504.
121. Ulloa L, Ochani M, Yang H, et al. 2002. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci U S A, 99:12351-6.
122. van der Poll T. 2001. Immunotherapy of sepsis. Lancet Inf Dis, 1:165-74.
123. van Deventer SJH, Buller HR, ten Cate JW, et al. 1990. Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic and complement pathways. Blood, 76:2520-6.
124. van Haren FM, Rozendaal FW, van der Hoeven JG. 2003. The effect of vasopressin on gastric perfusion in catecholamines-dependent patients in septic shock. Chest, 124:2256-60.
125. Vincent JL, Sun Q, Dubois MJ. 2003a. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Inf Dis, 34:1084-93.
126. Vincent JL, Sundin DP, Trzaskoma BL, et al. 2003b. Change in first day vasopressor use is predictive of outcome in severe sepsis, regardless of steroid use. Crit Care Med, 12(Suppl):A116.
127. Vincent JL, Levy MM, Macias WL, et al. 2003c. Early intervention with drotrecogin alfa (activated) improves survival benefit. Crit Care Med, 12(Suppl):A123.
128. Wagner HN Jr, Braunwald E. 1956. The pressor effect of the antidiuretic principle of the posterior pituitary in orthostatic hypotension. J Clin Invest, 35:1412-18.
129. Wang H, Bloom O, Zhang M, et al. 1999. HMG-1 as a late mediator of endotoxin lethality in mice. Science, 285:248-51.
130. Want L, Brown J, Varki A, et al. 2002. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest, 110:127-36.
131. Warr TA, Rao LV, Rapaport SI. 1990. Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity. Blood, 75:1481-9.
132. Warren HS, Suffredini AF, Eichacker PQ, et al. 2002. Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med, 347:1027-30.
133. Wesselschmidt R, Likert K, Huang Z, et al. 1993. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Blood Coag Fibrin, 4:713-20.
134. Weycker D, Akhras KS, Edelsberg J, et al. 2003. Long-term mortality and medical care charges in patients with severe sepsis. Crit Care Med, 31:2316-23.
135. Wheeler AP, Steingrub J, Linde-Zwirble W, et al. 2003a. Prompt administration of drotrecogin alfa (activated) is associated with improved survival. Crit Care Med, 12(Suppl):A120
136. Wheeler AP, Doig C, Wright T, et al. 2003b. Baseline characteristics and survival of adult severe sepsis patients treated with drotrecogin alfa (activated) in a global, single-arm, open-label trial (ENHANCE). Chest, 124(Suppl):S91.
137. Witthaut R, Busch C, Fraunberger P, et al. 2003. plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med, 29:1696-702.
138. Wood CE, Chen HG. 1989. Acidemia stimulates ACTH, vasopressin and heart rate responses in fetal sheep. Am J Phys, 257:R344-9.
139. Yan SB, Helterbrand JD, Hartman DL, et al. 2001. Low levels of protein C are associated with poor outcomes in severe sepsis. Chest, 120: 915-22.
140. Yang H, Ochani M, Li J, et al. 2004. Reversing established sepsis with antagonists of endogenous HMGB1. Proc Natl Acad Sci U S A, 101:296-301.
141. Zeng W, Matter WF, Yan SB, et al. 2004. Effect of drotrecogin alfa (activated) on human endothelial cell permeability and Rho kinase signaling. Crit Care Med, 32(Suppl 5):S302-8.
142. Zeni F, Freeman B, Natanson C. 1997. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment (editorial). Crit Care Med, 25:1095-100.